Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite Inc. (AMST) reported fiscal 2026 revenue of $364,777, compared with $110,459 in fiscal 2025. It launched a census-based NurseMagic™ Enterprise tier with electronic medical record compatibility, automated interdisciplinary team reporting and configurable documentation, introduced NurseMagic™ EMR capability, and secured its largest enterprise deployment, serving an approximately 2,700-patient census.
Net loss was $3,095,838, compared with $3,617,086 in fiscal 2025; operating cash used was $2,146,717. The April 2026 registered and private placements generated approximately $2.6 million in gross proceeds. Cash, cash equivalents and restricted cash totaled $2,398,809 as of June 30, 2026. Management said it may not have sufficient cash to maintain planned operations for the next 12 months following issuance of the financial statements. Its plans to generate cash through financing transactions are subject to market conditions and outside the company’s control; management concluded they do not alleviate substantial doubt about Amesite’s ability to continue as a going concern.
Amesite Inc. (AMST) disclosed that its next Annual Meeting of Stockholders will be held on December 10, 2026, with details on time, location and agenda to be provided in the forthcoming proxy statement.
Stockholders seeking to include proposals in the proxy statement under Rule 14a-8 must deliver them to the Company’s Secretary by the close of business on September 27, 2026. For other business or director nominations under the Company’s Bylaws (not using Rule 14a-8), notice must also be received by September 27, 2026, and any stockholder intending to solicit proxies in support of director nominees must provide the additional Rule 14a-19 notice by October 13, 2026.
Amesite Inc. (AMST) furnished updated shareholder presentation materials highlighting its AI-powered NurseMagic and LynkMagic platforms for the post‑acute care market, to be used at investor meetings including the H.C. Wainwright 28th Annual Global Investment Conference.
The materials describe a focus on the roughly $1.5T U.S. post‑acute and adjacent care segments, with users in 50 states and 21 countries and strong app ratings (5.0 in the App Store and 4.3 on Google Play). Amesite outlines a progression from a B2C NurseMagic app to enterprise deployments including a ~2,700‑patient census and an owner‑level view across 24 communities. The deck summarizes an April 2026 capital raise totaling $2 in gross proceeds across three tranches, including 696,866 shares sold at $1.435 per share and associated pre‑funded and Series A‑1/A‑2 warrants. It also notes no debt, estimates 16 months of cash burn coverage on hand under conservative assumptions, and positions Amesite as building AI infrastructure that integrates with existing healthcare systems.
Amesite Inc. entered into an At The Market Offering Agreement on July 17, 2026 with H.C. Wainwright & Co., LLC as sales agent, allowing Amesite to offer and sell shares of its common stock from time to time, up to a maximum aggregate offering price defined as the “Maximum Amount” in the agreement. Sales will be made as at-the-market offerings on The Nasdaq Capital Market or by other permitted methods at market prices or as otherwise agreed with the agent, under an effective Form S-3 shelf registration statement and related prospectus supplement.
H.C. Wainwright will use commercially reasonable efforts to execute sales based on Amesite’s instructions, and Amesite is not obligated to sell any shares, nor is the agent obligated to purchase shares on a principal basis. Amesite will pay a 3.0% commission on aggregate gross proceeds from each sale and reimburse specified expenses, including up to $50,000 of the agent’s legal fees and costs. Net proceeds, if any, are intended for general corporate and working capital purposes, with management retaining broad discretion over their allocation. The at-the-market program will end when all shares covered by the agreement are sold or the agreement is terminated under its terms.
Amesite Inc., an AI-focused healthcare technology company, established an at-the-market equity program with H.C. Wainwright & Co. to sell up to $2,266,112 of common stock from time to time. Shares may be sold on Nasdaq under the symbol AMST, with Wainwright acting as sales agent and earning a 3.0% commission on gross proceeds.
As of March 31, 2026, common shares outstanding were 4,748,001, and assuming sales of 1,970,532 shares at an illustrative price of $1.15, shares outstanding would rise to 8,520,383. At that assumed level, as adjusted net tangible book value would increase to $0.34 per share, implying immediate dilution of $0.81 per share to new investors. Amesite plans to use any net proceeds for general corporate and working capital purposes while warning that investing in its stock involves a high degree of risk and that it does not anticipate paying cash dividends.
Amesite Inc. reported results of its July 13, 2026 annual meeting of stockholders. Stockholders of record on May 22, 2026, when 5,852,985 shares of common stock were outstanding, were entitled to vote. A total of 2,321,797 shares, or approximately 40% of outstanding shares, were represented, constituting a quorum under the company’s bylaws. Stockholders elected Ann Marie Sastry, Ph.D. and Barbie Brewer as Class II directors for three-year terms and ratified Novogradac & Company LLP as independent registered public accounting firm for the year ending June 30, 2026.
Stockholders also approved amending the 2018 Equity Incentive Plan to increase the number of shares available for issuance under the plan by 1,000,000 shares and separately increase the number of shares that may be issued pursuant to the exercise of incentive stock options by 1,000,000 shares. In addition, in accordance with Nasdaq Listing Rule 5635(d), stockholders approved the issuance of an aggregate of 1,393,732 shares of common stock upon exercise of the company’s Series A-1 warrants and an aggregate of 1,393,732 shares of common stock upon exercise of its Series A-2 warrants.
Amesite Inc. reported that Chief Financial Officer Sarah Berman received a grant of stock options as part of her compensation. The award covers 10,000 options to purchase common stock at an exercise price of $1.1400 per share, expiring on June 29, 2036. According to the vesting terms, 25% of the options vest on June 29, 2027, and the remaining options vest in equal monthly installments over the following 36 months. After this grant, she holds 10,000 stock options directly.
Amesite Inc. chief financial officer Sarah Berman reported a compensation-related stock option grant. She received options to buy 2,500 shares of common stock at an exercise price of $3.05 per share, expiring on May 22, 2035. According to the vesting terms under the 2018 Equity Incentive Plan, 25% of the shares vest on May 22, 2026, with the remaining shares vesting in equal monthly installments over 36 months.
Parmer George reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director George Parmer received a grant of 9,023 restricted stock units as compensation. These RSUs were issued as deferred stock units in lieu of cash fees earned for serving as a director, with the number based on the closing share price on the last day of the quarter.
Each unit represents a right to receive one share of Amesite common stock or the cash equivalent. The deferred stock units or cash equivalent will be delivered after Parmer completes service on the board or upon an earlier change in control. Following this award, his directly held equity position reported in this filing totals 76,910 shares or share-equivalent units.
OMENN GILBERT S reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, received a grant of 9,023 restricted stock units as compensation for board service. Each RSU represents a contingent right to one share of common stock or its cash equivalent, to be delivered after board service ends or upon a change in control. Following this award, indirect holdings reported for this trust total 83,806 shares underlying RSUs.